Gregg Stone, MD, spoke to Cardiovascular Business about early data from the ATHENS-HF trial. Ten heart failure patients were treated with the adjustable device, and each implant was a success. 
 

Performing M-TEER and T-TEER on the same patient using a single guide catheter appears to be both safe and effective. Researchers shared their experience with this approach in Circulation: Cardiovascular Interventions.

The U.S. Food and Drug Administration has green-lit new updates that improve microvascular flow, AI-assisted harmonic imaging and elastography, which Canon will showcase at RSNA 2025.

The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Jaimin Chung, director of Canon Medical’s interventional X-ray and vascular business unit, explains the technology behind a new combined CT angiography interventional system aimed at neurology, trauma, stroke and pediatrics that recently received 510(k) FDA clearance.

The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.

About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.